In this review, we highlight the recent progress and difficulties in CD47/SIRPα targeted drug development for cancer immunotherapy, look into future perspectives, and explore potential solutions to improve CD47/SIRPα targeted drug development. This evidence concerns the gene SIRPA and cancer.